ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2,1,Rash follicular,Pustular conditions,Epidermal and dermal conditions,Skin,N
3,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
3,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
4,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
4,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
6,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
7,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
8,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
8,2,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
8,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
8,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
8,5,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
8,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
9,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
10,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
11,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
12,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
12,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,3,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
13,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
13,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
13,3,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
13,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
13,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
13,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
14,1,Vulvovaginal burning sensation,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
15,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
15,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
17,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
